A554 Impaired Stem Cell Mobilization by Fludarabine in MM: Results from a Randomized Phase II Trial

Autor: S Lennhoff, Niels Frost Andersen, Anne K. Mylin, Niels Abildgaard, Annette Juul Vangsted, Torben Mourits-Andersen, Christian Gluud, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Tangen, JL Nielsen, LM Knudsen, Torben Plesner, P Gimsing, Hans Gregersen

Publikováno v: Clinical Lymphoma and Myeloma. 9:S85

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a163e59ea1634424cfebe5b0b1adffce
https://doi.org/10.1016/s1557-9190(11)70620-5

Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group

Autor: Lm, Knudsen, Hippe E, Hjorth M, Erik Holmberg, Westin J

Publikováno v: Europe PubMed Central

This study describes the occurrence of renal failure among 1353 newly diagnosed cases of multiple myeloma. Renal function was evaluated by serum creatinine concentration in 1353 cases, 31% of whom had renal failure at the time of diagnosis. In 1206 c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1567b63205ee0c8d4123e7f6cbb47421
http://europepmc.org/abstract/med/7957804

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.

Autor: Jørgensen NG; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Klausen U; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Grauslund JH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Helleberg C; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Aagaard TG; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Do TH; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Ahmad SM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Olsen LR; Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark., Klausen TW; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Breinholt MF; Department of Pathology, Copenhagen University Hospital, Herlev, Denmark., Hansen M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Martinenaite E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Met Ö; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Knudsen LM; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: Frontiers in immunology [Front Immunol] 2020 Nov 09; Vol. 11, pp. 595035. Date of Electronic Publication: 2020 Nov 09 (Print Publication: 2020).

[Cancer immune therapy for the treatment of haematological malignancies].

Autor: Holmström MO; holmeren1@yahoo.dk., Klausen U, Jørgensen NG, Holmberg S, Grauslund J, Met Ö, Svane IM, Pedersen LM, Knudsen LM, Hasselbalch HC, Andersen MH

Publikováno v: Ugeskrift for laeger [Ugeskr Laeger] 2019 Mar 04; Vol. 181 (10).

The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin 43 to promote loss of gap junctions.

Autor: Totland MZ; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; Institute for Biosciences, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway., Bergsland CH; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; Institute for Biosciences, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway., Fykerud TA; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway., Knudsen LM; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; Institute for Biosciences, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway., Rasmussen NL; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; Institute for Biosciences, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway., Eide PW; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway., Yohannes Z; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway., Sørensen V; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway.; Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway., Brech A; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; Institute for Biosciences, University of Oslo, 0316 Oslo, Norway.; Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway., Lothe RA; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; Institute for Biosciences, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway., Leithe E; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway eleithe@rr-research.no.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway.; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, 0424 Oslo, Norway.

Publikováno v: Journal of cell science [J Cell Sci] 2017 Sep 01; Vol. 130 (17), pp. 2867-2882. Date of Electronic Publication: 2017 Jul 21.